RecruitingNot Applicable

Registry Platform Gastric/Esophageal Cancer (SAPHIR)

Germany1,900 participantsStarted 2019-12-04

Plain-language summary

The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC * Planned palliative systemic first-line therapy * Age \>= 18 years * Signed informed consent (IC) * Patients answering questionnaires: IC before first therapy cycle * Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle Exclusion Criteria: * No systemic therapy for ESCC, EAC, GAC or GEJAC

What they're measuring

Course of treatment (treatment reality)

Timeframe: 2 years per patient

Trial details

NCT IDNCT04290806

SponsoriOMEDICO AG

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-12-31

Contact for this trial

Adrian Binninger

+49 761 152 42 - 0 info@iomedico.com

View on ClinicalTrials.gov More Esophageal Squamous Cell Carcinoma trials